Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
Aerospace systems provider Astronics Corporation launches its new automated circuit card testing system, designed to accelerate troubleshooting and maintenance for critical aviation and defense electronics, as analysts raise price targets on sustained sector demand.
Erasca (ERAS) gains significant analyst momentum as Mizuho initiates coverage with an 'Outperform' rating and a $16 price target, citing confidence in its 2026 proof-of-concept milestones for RAS-targeted cancer therapies.
ABIVAX (NASDAQ:ABVX) shares have skyrocketed over 2000% in recent months, fueled by speculation of an Eli Lilly buyout and promising clinical data for its lead drug. CEO Marc De Garidel has publicly dismissed the acquisition rumors as 'noise,' redirecting focus to the company's financing needs and advancing therapeutic programs.
Roth Capital has upgraded Energy Fuels (UUUU) from 'Sell' to 'Neutral', raising its price target to $15. The move follows the uranium miner's strategic acquisition of Australian Strategic Materials, expanding its rare earths portfolio and positioning within Western critical mineral supply chains.
February opens with a brutal sell-off across digital assets, seeing over $2.5 billion in liquidations and pushing Ethereum to the brink of $2,000. The turmoil coincides with a historic drop in gold, fueling debates on market stability and the path forward.
Alphabet's self-driving subsidiary Waymo is reportedly seeking a new funding round that would value the company at approximately $110 billion, drawing fresh attention to the tech giant's ambitious bets beyond its core advertising business and the evolving landscape of autonomous vehicle investment.
Audius SE (FRA:3ITN) shares jumped 13% last week, prompting a closer look at whether the rally is backed by the company's financial health or driven by broader market sentiment.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
Klaviyo deepens its AI capabilities with a new ChatGPT integration and a key partnership, aiming to enhance marketer tools and customer data—a strategic push as the company navigates profitability challenges and a depressed stock price.
Jacobs Solutions lands pivotal roles in California wastewater upgrades and UK nuclear project, reinforcing its position in sustainable infrastructure despite shares trading below analyst targets.
While geopolitical tensions have rattled regional markets, a closer look reveals resilient smaller companies in the GCC and Turkey offering unique value propositions. We analyze three firms with market caps under $900 million in the education, packaging, and industrial sectors.
As Thailand heads to the polls, Prime Minister Anutin Charnvirakul—a master political operator known for his ability to navigate crises—seeks to retain power. His tenure has been marked by strategic reversals, controversial policies, and the delicate balancing of conservative elites and public expectations.
In a landmark deal reshaping the U.S. energy landscape, NRG Energy has completed its acquisition of LS Power's 13GW natural gas fleet and virtual power plant platform, significantly boosting its capacity and demand-response capabilities in key markets.
Chevron's fourth-quarter profit fell 12.5% year-over-year, pressured by lower oil prices, but the energy giant highlighted robust operational cash flow, record production levels following its Hess acquisition, and significant progress in its long-term strategic projects.
A $100 investment in Nvidia stock a decade ago would now be worth over $27,000, illustrating one of the most remarkable growth stories in modern market history, driven by the company's pivotal role in the AI revolution.
With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.
The Hong Kong Monetary Authority (HKMA) is poised to grant its inaugural stablecoin issuer licenses in March, with approvals expected for only a select few firms. The move transitions the city's digital asset framework from sandbox testing to a formally regulated market, focusing on stringent risk controls and credible use cases.
Leading Solana DEX aggregator Jupiter has finalized a $35 million strategic investment from ParaFi Capital, with the landmark deal to be settled entirely in its native stablecoin, JupUSD. The move signals strong institutional validation and a push for JupUSD adoption.
President Trump's apparent endorsement of a weaker dollar is not mere rhetoric but a strategic pillar of his economic agenda, aimed at boosting US competitiveness and narrowing the trade deficit, with significant implications for global central banks and currency markets.
